Australia markets close in 30 minutes

SNY Jan 2025 45.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.75000.0000 (0.00%)
As of 09:30AM EDT. Market open.
Full screen
Previous close1.7500
Open1.7500
Bid0.0000
Ask0.0000
Strike45.00
Expiry date2025-01-17
Day's range1.7500 - 1.7500
Contract rangeN/A
Volume13
Open interestN/A
  • Zacks

    Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag

    The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.

  • GlobeNewswire

    Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

    Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of Clinical Oncolog

  • Reuters

    Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million

    A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million. The ruling from Judge James Ashford, of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.